Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Subscribe To Our Newsletter & Stay Updated
